This article originally appeared on The Conversation. You can read it here.

I am a physician and a scientist at the University of Virginia. I care for patients and conduct research to find better ways to diagnose and treat infectious diseases, including COVID-19. Here I’m sharing what is known about which treatments work, and which don’t, for the new coronavirus infection.

Keep in mind that this field of medicine is rapidly evolving as our understanding of the SARS-CoV-2 virus improves. So what I am writing today may change within days or weeks.

Below are the treatments that have been tried and for which we have the best knowledge.


Hydroxychloroquine or chloroquine – no evidence they work

There are three randomized controlled trials of hydroxychloroquine, all of which have failed to prove or disprove a beneficial or harmful effect on COVID-19 clinical course or clearance of virus. Given this current lack of evidence, these drugs, which normally are used to treat arthritis, should only be used within the context of a controlled clinical trial.

Lopinavir/ritonavir – not helpful

The drug Lopinavir is an inhibitor of an enzyme called HIV protease which is involved in the production of viral particles. Protease inhibitors for HIV were revolutionary, leading to our current ability to effectively treat HIV. Lopinavir also can inhibit enzymes that perform similar functions as the HIV protease in the SARS and MERS coronaviruses. Ritonavir increases the level of Lopinavir in the blood so the lopinavir/ritonavir combination was tested in a randomized controlled clinical trial for COVID-19.

Unfortunately, there was no impact on the levels of virus in the throat or duration of viral shedding, nor did patients’ clinical course or survival change. There therefore is no role for lopinavir/ritonavir in the treatment of COVID-19.

Steroids – yes for almost all COVID-19 patients

When a synthetic steroid hormone, called dexamethasone, was given to patients with COVID-19 the drug decreased 28-day mortality by 17% and hastened hospital discharge.

This work was performed in a randomized and controlled clinical trial of over 6,000 patients, and while not replicated in another study or yet peer reviewed, is certainly enough evidence to recommend its use.

Tocilizumab – too early to judge

Tocilizumab is an antibody, that blocks a protein, called IL-6 receptor, from binding IL-6 and triggering inflammation. Levels of IL-6 are higher in many patients with COVID-19, and the immune system in general seems to be hyperactivated in those with the most severe disease. This leads many physicians and physicians to think that inhibiting the IL-6 receptor might protect patients from severe disease.

Tocilizumab is currently FDA approved for the treatment of rheumatoid arthritis and several other collagen-vascular diseases and for “cytokine storm” – a harmful overreaction of the immune system – that can be caused by certain types of cancer therapy and COVID-19.

A retrospective observational study found that COVID-19 patients treated with tocilizumab had a lower risk of mechanical ventilation and death. But we lack a randomized controlled clinical trial so there is no way to ascertain if this apparent improvement was due to tocilizumab or from the imprecise nature of retrospective studies.

Convalescent plasma – too early to judge

Convalescent plasma, the liquid derived from blood after removing the white and red blood cells, contains antibodies from previous infections that the plasma donor had. This plasma has been used to prevent infectious diseases including pneumonia, tetanus, diphtheria, mumps and chickenpox for over a century. It is thought to benefit patients because antibodies from the plasma of survivors bind to and inactivate pathogens or their toxins of patients. Convalescent plasma has now been used in thousands of COVID-19 patients.

However, the only randomized clinical trial was small and included just 103 patients who received convalescent plasma 14 days after they became ill. There was no difference in the time to clinical improvement or mortality between those who did and did not receive treatment. The encouraging news was that there was a significant decrease in virus levels detected by PCR.

It is therefore too early to tell if this will be beneficial and controlled clinical trials are needed.

Remdesivir – yes, decreases hospital stay

Remdesivir is a drug that inhibits the coronavirus enzyme that makes copies of the viral RNA genome. It acts by causing premature stoppage or termination of the copying and ultimately blocks the virus from replicating.

Remdesivir treatment, especially for patients who required supplemental oxygen before they were placed on a ventilator reduced mortality and shortened the average recovery time from 15 to 11 days.

ACE inhibitors and ARBs – keep taking them

There was a concern that drugs called ACE inhibitors or angiotensin receptor blockers (ARBs), which are used to treat high blood pressure and heart failure, could increase levels of the ACE2 proteins, the receptor for SARS-CoV-2, on the surface of cells in the body. This would, physicians hypothesized, allow more entry points for the virus to infect cells and would therefore boost the severity of new coronavirus infections.

However, there is no evidence that this is the case. The American Heart Association, the Heart Failure Society of America and the American College of Cardiology all recommend that patients continue to take these medications during the pandemic as they are beneficial in the treatment of high blood pressure and heart failure.

We have made amazing progress in the treatment of COVID-19. Two therapies – steroids and Remdesivir – have already been shown to help. Those who benefit from these treatments owe thanks to patients who volunteered to participate in controlled clinical trials, and the physicians and pharmaceutical companies that lead them.


William Petri is Professor of Medicine, University of Virginia

  • New Russian research suggests that the human lifespan could be up to 156 years
    Photo credit: CanvaResearchers found what's preventing us from living longer.
    ,

    New Russian research suggests that the human lifespan could be up to 156 years

    Humans can live much longer if certain barriers are addressed.

    According to the Guinness Book of World Records, the oldest person lived to the ripe age of 122 years old. Such a lifespan is an incredible feat, but what if the average person could beat that record by 34 years? Recent research done in Russia has led scientists to believe that the average human lifespan could be up to 156 years.

    The researchers at Skoltech Biomed Technologies Center developed a mathematical model that allowed them to “switch on” a variety of aging mechanisms. This allowed them to calculate a human’s lifespan where mortality risk never increased with age. After experimenting with different scenarios and conditions, they found the biggest barriers to longevity were caused by non-renewable tissues and somatic mutations.

    What are these barriers against longer life?

    Somatic mutations are DNA changes within a cell. They accumulate over time during a human’s life and cannot be reversed with any existing therapy. These DNA errors that pile up in our cells contribute to the aging process.

    Many human organs like the liver and skin continually replace cells and regrow damaged portions of themselves. However, there are two organs that can’t do this: the brain and the heart. Brain tissue (neurons) and heart tissue (cardiomyocytes) cannot regenerate. This proves to be the most prominent biological limit that shortens our lifespans. This explains why issues like dementia and heart disease are prominent causes of death and morbidity later in life. Since those organs’ tissues don’t replace damaged cells, they’re prone to irrevocably decline over time.

    “The key finding of the study is the discovery of substantial differences between tissue types. Neurons and cardiomyocytes, which lack the ability to divide, turned out to be the main limiting factors: when all other causes of aging are eliminated, somatic mutations alone reduce the theoretical median lifespan from 1,759 years (for a hypothetical non-aging human organism) to 156 years,” said Evgeny Efimov, a research intern at the Skoltech Biomed Technologies Center, researcher at AIRI, and one of the key authors of the study.

    This suggests that somatic mutations and DNA damage is what ultimately prevents humans from living indefinitely, even if our brains and hearts regenerated cells like other organs.

    So what’s next?

    Now knowing these biological limitations, the researchers hope to study other areas of aging impacting the human lifespan that could plausibly be reversed. This includes mitochondrial dysfunction, telomere shortening, epigenetic drift, and loss of proteostasis. 

    The hope is to have a clearer priority list of issues for future therapies to tackle. This is not just to possibly extend life, but to improve lives in general. By developing a fully comprehensive theory of aging, Skoltech hopes to pinpoint which aspects of aging are within our scope to address. After all, thoroughly studying each puzzle piece that makes up human life gives us a better understanding of the whole.

    Of course, other impactful factors in a person’s lifespan can be addressed today. As most know, things like diet, sleep, and exercise are among them. A person’s living environment can also negatively impact their lifespan if it doesn’t have clean air, access to clean water, and so on.

    For now, the best method for living long is to follow instructions from your physician. Whether you make it to 156 years or not, living well is best for whatever time you’re given.

  • Screen time guidelines for kids and adolescents have shifted as research paints a more nuanced picture
    Photo credit: PeopleImages/iStock via Getty ImagesWhat kids are doing on tablets seems to matter more than how long they use them.

    Concerns surrounding young people’s screen time are widespread.

    Australia became the first country to ban social media for users under 16 in December 2025, and DenmarkFrance and the U.K. have since announced similar restrictions to begin this year.

    In the U.S., as of mid-2026, more than 30 states have passed laws banning or restricting cellphones in K–12 classrooms; in 2023, the U.S. surgeon general issued a formal advisory on social media and children’s and adolescents’ mental health; and bestselling books tell parents that smartphones are “rewiring” their children’s brains.

    These concerns and policies are part of a quickly changing national and international conversation around how young people spend time on screens and its relationship to their overall health and development. My reading of the mounting research on this issue across disciplines is that the popular narrative blaming screens and smartphones for an adolescent mental health crisis runs well ahead of the current evidence.

    I study adolescent digital media use and its influence on social, emotional and academic outcomes. A growing body of research suggests that one-size-fits-all solutions are not the answer and that managing appropriate use of digital media needs to take into account a child’s developmental milestones, how parents and adults around them use media, and the ways kids use it to connect and learn with friends and family.

    Screen time: From monolith to multifaceted

    Wide adoption of digital media and the internet broadened the range of experiences young people could have online. At the same time, the digital age introduced newfound uncertainties. As with the advent of radio, comic books and arcades, adults worried about how children might interact with or be affected by internet use.

    In response, the American Academy of Pediatrics first recommended in 1999 that parents and caregivers keep children under 2 away from screens. In the decades since, professional guidance largely treated children’s media use as a behavior to be mitigated.

    Policies introduced by the academy in 2013 and 2016 continued to advise that school-age kids and adolescents – those ages 5 to 18 – be restricted to no more than two hours of “entertainment” screen time a day. The goal was to curb risks associated with heavy media use, among them disrupted sleep, online safety, cyberbullying and physical inactivity.

    Originally created for young people’s engagement with stationary media that tend to be confined to one room or context – for example, watching television – these hourly limits became outdated with the integration of smartphones and other digital devices into everyday life. Compared with watching television, online media was far more difficult to track and define, and more nuanced in its use.

    Developmentally beneficial activities such as educationsocializing and leisure have come to rely on the internet to extend and maintain face-to-face connections. Remote schooling and social distancing during the COVID-19 pandemic only accelerated this digitization of daily life.

    In my view, adopting strict time limits and restrictions could pose risks to children’s well-beingautonomy and development, for example, by harming adolescent self-esteem.

    The latest guidelines

    In January 2026, the American Academy of Pediatrics retired its decade-old framework that had largely organized its advice around hourly screen limits. The new policy statement on children, adolescents and digital media diverges from this blanket approach. Instead, it suggests parents consider the larger picture in which this media use exists rather than lumping all screen use together.

    Similar to the World Health Organization’s 2019 guidance for children under 5, the American Academy of Pediatrics still advises that parents avoid screen media for children younger than 18 months. This recommendation is largely because extended use by children by themselves can be problematic for many young children, crowding out important developmental milestones.

    Both the World Health Organization and the American Academy of Pediatrics also recommend that when children under 24 months use screens, they should be limited to content and devices that encourage children and caregivers to interact. For ages 2 to 5, screen time – including TV and interactive apps on devices – may be extended to more solo use, provided it’s high-quality digital media designed around learning goals in mathematics and reading. But recreational use should be limited to roughly an hour per day.

    For school-age children and teens, the newest guidance has begun to step away from fixed screen time limits and asks families to weigh online activity in the context of everyday life.

    Doing so recognizes that a child’s digital experiences are shaped by diverse factors rather than the hours spent online. Current guidelines call on caregivers to distinguish among types of media, from television and social media to video games and interacting with artificial intelligence chatbots. They also call for taking into account a child’s individual characteristics, such as their interests and personality, family members’ own use of screens, and the type of content children are spending time on.

    Rethinking screen time

    Moving beyond strict screen time limits includes questioning the kind of digital activities kids and adolescents participate in. Do the activities encourage time spent interacting with others online, which can help young people develop important skills and competencies?

    Scrolling an algorithm-based, auto-playing video feed likely does not equate to the same opportunities as video-chatting with friends, creating digital art or working with teammates in a multiplayer game. Research suggests these different uses relate to development in different ways and can help kids develop varying skill sets pertaining to everyday life and schooling.

    Indeed, a large review of current research found that young people who take part in a range of digital activities, such as browsing the web, online gaming or interacting on social media, show positive associations with social connection, identity exploration, civic participation and learning.

    A woman and two small children look at tablet screen
    Parental involvement in young children’s screen time has developmental benefits. Cultura Creative/Tetra images via Getty Images

    Using these guidelines at home

    The current evidence suggests parents and caregivers are best positioned to be digital instructors. Cutting children off altogether can carry its own risks for social and emotional development. Caregiver mediation of children’s screen time can produce widely different outcomes and effects, depending on whether the guidance is supportive or controlling.

    Considering your own digital media use is the first step: Are family members engaging in problematic or heavy media use that children in the household might emulate? What applications and uses are most common in the family, and what positive or negative effects might they have, depending on the child’s age? How could these digital activities be safely integrated with other everyday experiences to increase their benefit for children? Conversely, what online time might be better spent on face-to-face experiences?

    The American Academy of Pediatrics’ Family Media Plan tool turns these ideas into concrete questions. For example, it recommends working out what each child needs from digital technology, what activities screens might be crowding out, and where their family or household can build in screen-free time. The recommendation is to talk with each child about why they are drawn to particular apps or online activities, what they encounter while browsing, and what might be lost when kids bring phones to gatherings such as mealtimes.

    The debate over young people’s screen time is not going away. But the most up-to-date guidelines, and the growing body of research behind them, make a strong case for a more holistic approach. The guidelines treat digital media as a complex, diverse and evolving environment that children need to learn to navigate in the digital age. The risks and rewards depend, as with any developmental setting, on the child, the content and what online time might be crowding out.

    This article originally appeared on The Conversation. You can read it here.

  • ER doctor and mom sets the record straight for parents of kids with e-bikes and e-scooters
    Photo credit: CanvaA boy rides an e-scooter, left, while a girl is examined in an emergency room.

    An emergency room doctor and fellow mom has been noticing a troubling trend: Many parents are giving their kids something more powerful than bicycles to get around the neighborhood. As a result, she’s seeing more children come into the ER with injuries sustained in e-bike and e-scooter crashes. She recently went online with a plea to parents and young riders.

    Dr. Meghan Elizabeth Beach Martin, known online as Dr. Beachgem, posted a video in her scrubs discussing her concerns after seeing so many children come into the hospital with e-bike injuries during the summer months. She’s worried that too many kids and parents don’t understand the proper safety precautions. As a mother herself, she even questions why children are allowed to ride these devices at all.

    In the video, the doctor explains that some e-bikes can reach speeds of up to 28 mph. She says that if an e-bike goes any faster than that, it’s technically classified as a motorcycle. At those speeds, she regularly sees children with traumatic injuries and broken bones after hitting bumps, cracks in the road, or other vehicles. Many of them aren’t wearing helmets or protective pads, and some are even riding barefoot, making their injuries even more severe. Martin’s video has gained traction on Reddit and elsewhere online.

    E-bikes and e-scooters, examined

    Martin isn’t the only professional seeing a growing problem. The American College of Surgeons reports that there are more than 20,000 e-bike-related injuries each year. Meanwhile, a University of California, San Francisco study found that e-bike injuries doubled annually from 2017 to 2022. The same study found that e-scooter injuries increased by 45% each year during the same period.

    Before riding an e-bike, it’s important to follow proper safety procedures. Make sure you and your child understand your area’s laws regarding e-bikes, including any minimum age requirements. Always wear a helmet and other protective gear when riding. Consider choosing an e-bike with safety features such as motor-interrupt brake levers and disc brakes. These are just a few of the many safety tips experts recommend.

    The U.S. Consumer Product Safety Commission has similar safety tips for e-scooter riders. Wearing a helmet is one of its top recommendations, along with taking other basic precautions. The agency also recommends checking the brakes before riding and slowing down for bumps, cracks, and other road hazards.

    The vast majority of e-scooters and e-bikes are designed for only one rider, so avoid doubling up. Although laws vary by state and locality, wearing more protective gear is always the safer choice. Riders should also review local e-bike and e-scooter laws to make sure they are operating the vehicles safely and legally.

    A little research goes a long way toward making sure you and your children can ride safely. It’s also important for parents to understand that many e-bikes and e-scooters can travel at speeds that make them very different from a traditional bicycle. The last thing you want is for you or your child to become another emergency room statistic.

Explore More Health Stories

Health

Screen time guidelines for kids and adolescents have shifted as research paints a more nuanced picture

Care

ER doctor and mom sets the record straight for parents of kids with e-bikes and e-scooters

Health

May cause joy: The full-spectrum health benefits of dance 

Research

Why we crave company